Información del producto
- Cgp 45715A
- (S-(R*,S*-(E,Z)))-7-((9-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-4H-1-benzopyran-2-carboxylic acid monosodium salt
- 1-Hydroxy-1-(3-trifluoromethylphenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid
- Cgp-45715 A
- 4H-1-Benzopyran-2-carboxylic acid, 7-((9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-, monosodium salt, (S-(R*,S*-(E,Z)))-
- sodium 7-{[(1S,2E,4Z)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-{(R)-hydroxy[3-(trifluoromethyl)phenyl]methyl}nona-2,4-dien-1-yl]sulfanyl}-4-oxo-4H-chromene-2-carboxylate
Iralukast Na is a leukotriene receptor antagonist that prevents bronchoconstrictor response. It binds to the cystic fibrosis transmembrane conductance regulator (CFTR) and blocks the binding of leukotrienes, which are potent bronchoconstrictors. Iralukast Na also blocks the activity of inflammatory cells and reduces bowel inflammation. Iralukast Na has been shown to be effective in treating asthma, inflammatory bowel disease, and other autoimmune diseases.
Propiedades químicas
Consulta técnica sobre: 3D-FS104155 Iralukast Na
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.